3 7 1 5 7

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊





更多详情 >>



会员计划

我们很高兴为机构提供一种切实的方法以支持开放获取并鼓励教师和研究人员通过开放获取模式尽可能广泛地传播他们的作品。

更多详情 >>

 

加入德孚官方微信,即可享受论文费用7.5折

视频

Biomarkers of Duchenne muscular dystrophy: current findings

 

Authors Al-Khalili Szigyarto C, Spitali P

Received 31 August 2017

Accepted for publication 24 November 2017

Published 25 January 2018 Volume 2018:8 Pages 1—13

DOI https://doi.org/10.2147/DNND.S121099

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Thomas Müller

Abstract: Numerous biomarkers have been unveiled in the rapidly evolving biomarker discovery field, with an aim to improve the clinical management of disorders. In rare diseases, such as Duchenne muscular dystrophy, this endeavor has created a wealth of knowledge that, if effectively exploited, will benefit affected individuals, with respect to health care, therapy, improved quality of life and increased life expectancy. The most promising findings and molecular biomarkers are inspected in this review, with an aim to provide an overview of currently known biomarkers and the technological developments used. Biomarkers as cells, genetic variations, miRNAs, proteins, lipids and/or metabolites indicative of disease severity, progression and treatment response have the potential to improve development and approval of therapies, clinical management of DMD and patients’ life quality. We highlight the complexity of translating research results to clinical use, emphasizing the need for biomarkers, fit for purpose and describe the challenges associated with qualifying biomarkers for clinical applications.
Keywords: diagnostic biomarkers, disease monitoring biomarkers, pharmacodynamic ­biomarkers, surrogate biomarkers, genetic modifiers, proteomic, metabolomic, lipidomic, imaging


 

摘要视频链接Biomarkers of Duchenne muscular dystrophy